In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation

References

• H. Wang, K. Lv, X. Li, B. Wang, A. Wang, Z. Tao, Y. Geng, B. Wang, M. Huang, and M. Liu, Design, synthesis and antimycobacterial activity of novel nitrobenzamide derivatives, Chin. Chem. Lett. 30 (2019), pp. 413–416. doi:10.1016/j.cclet.2018.08.005.
   Web of Science ®Google Scholar
• S. Datta and C.A. Evans, Healthy survival after tuberculosis, Lancet Infect. Dis. 19 (2019), pp. 1045–1047. doi:10.1016/S1473-3099(19)30387-1.
   PubMed Web of Science ®Google Scholar
• A. Jain and R. Mondal, Extensively drug-resistant tuberculosis: Current challenges and threats, FEMS. Immunol. Med. Mic. 53 (2008), pp. 145–150. doi:10.1111/j.1574-695X.2008.00400.x.
   PubMed Web of Science ®Google Scholar
• A.A. Velayati, P. Farnia, and S. Hoffner, Drug-resistant Mycobacterium tuberculosis: Epidemiology and role of morphological alterations, J. Glob. Antimicrob. Res. 12 (2018), pp. 192–196. doi:10.1016/j.jgar.2017.10.006.
   PubMed Web of Science ®Google Scholar
• H. Verma, S. Choudhary, P.K. Singh, A. Kashyap, and O. Silakari, Decoding the signature of molecular mechanism involved in mutation associated resistance to 1, 3-benzothiazin-4-ones (Btzs) based DprE1 inhibitors using BTZ043 as a reference drug, Mol. Simulat. 45 (2019), pp. 1515–1523. doi:10.1080/08927022.2019.1659507.
   Web of Science ®Google Scholar
• Organization WH (2018) Global tuberculosis report 2016.
   Google Scholar
• A. Khan, A. Asghar, K. Hashmi, M. Farooq, B. Shaheen, and I. Ali, Mycobacterium tuberculosis: Pattern of first line drug resistance, APMC 13 (2019), pp. 80–83. doi:10.29054/APMC/19.563.
   Google Scholar
• C. Trefzer, M. Rengifo-Gonzalez, M.J. Hinner, P. Schneider, V. Makarov, S.T. Cole, and K. Johnsson, Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis, J. Am. Chem. Soc. 132 (2010), pp. 13663–13665. doi:10.1021/ja106357w.
   PubMed Web of Science ®Google Scholar
• M. Panda, S. Ramachandran, V. Ramachandran, P.S. Shirude, V. Humnabadkar, K. Nagalapur, S. Sharma, P. Kaur, S. Guptha, and A. Narayan, Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity, J. Med. Chem. 57 (2014), pp. 4761–4771. doi:10.1021/jm5002937.
   PubMed Web of Science ®Google Scholar
• R.V. Chikhale, M.A. Barmade, P.R. Murumkar, and M.R. Yadav, Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis, J. Med. Chem. 61 (2018), pp. 8563–8593. doi:10.1021/acs.jmedchem.8b00281.
   PubMed Web of Science ®Google Scholar
• R. Sommer, J. Neres, J. Piton, N. Dhar, A. Van Der Sar, R. Mukherjee, T. Laroche, P.J. Dyson, J.D. McKinney, and W. Bitter, Fluorescent benzothiazinone analogues efficiently and selectively label dpre1 in Mycobacteria and Actinobacteria, ACS Chem. Biol. 13 (2018), pp. 3184–3192. doi:10.1021/acschembio.8b00790.
   PubMed Web of Science ®Google Scholar
• Y. Gao, J. Xie, R. Tang, K. Yang, Y. Zhang, L. Chen, and H. Li, Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening, Bioorg. Chem. 85 (2019), pp. 168–178. doi:10.1016/j.bioorg.2018.12.018.
   PubMed Web of Science ®Google Scholar
• H. Verma and O. Silakari, Benzoxazolinone: A scaffold with diverse pharmacological significance, in Key Heterocycle Cores for Designing Multitargeting Molecules, O. Silakari, ed., Elsevier, Amsterdam, The Netherlands, 2018, pp. 343–367. doi:10.1016/B978-0-08-102083-8.00010-8.
   Google Scholar
• G.S. Pedgaonkar, J.P. Sridevi, V.U. Jeankumar, S. Saxena, P.B. Devi, J. Renuka, P. Yogeeswari, and D. Sriram, Development of benzo [d] oxazol-2 (3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA, Bioorg. Med. Chem. 22 (2014), pp. 6134–6145. doi:10.1016/j.bmc.2014.08.031.
   PubMed Web of Science ®Google Scholar
• A. Suwattanamala and V. Ruangpornvisuti, Isomeric structures of benzimidazole, benzoxazole, and benzothiazole derivatives, their electronic properties and transformations, Struct. Chem. 20 (2009), pp. 619–631. doi:10.1007/s11224-009-9454-8.
   Web of Science ®Google Scholar
• P. Xiang, T. Zhou, L. Wang, C.Y. Sun, J. Hu, Y.L. Zhao, and L. Yang, Novel benzothiazole, benzimidazole and benzoxazole derivatives as potential antitumor agents: Synthesis and preliminary in vitro biological evaluation, Molecules 17 (2012), pp. 873–883. doi:10.3390/molecules17010873.
   PubMed Web of Science ®Google Scholar
• J. Kočı́, V. Klimešová, K. Waisser, J. Kaustová, H.M. Dahse, and U. Möllmann, Heterocyclic benzazole derivatives with antimycobacterial in vitro activity, Bioorg. Med. Chem. Lett. 12 (2002), pp. 3275–3278. doi:10.1016/S0960-894X(02)00697-2.
   PubMed Web of Science ®Google Scholar
• S. Uenlue, T. Oenkol, Y. Duendar, B. Oekcelik, E. Kuepeli, E. Yeşilada, N. Noyanalpan, and M.F. Şahin, Synthesis and analgesic and anti‐inflammatory activity of some new (6‐acyl‐2‐benzoxazolinone and 6‐acyl‐2‐benzothiazolinone derivatives with acetic acid and propanoic acid residues, Arch. Pharm. 336 (2003), pp. 353–361. doi:10.1002/ardp.200300746.
   PubMed Web of Science ®Google Scholar
• S. Haider, M.S. Alam, H. Hamid, A. Dhulap, S. Umar, M.S. Yar, S. Bano, S. Nazreen, Y. Ali, and C. Kharbanda, Design, synthesis and docking studies of 2-benzoxazolinone-based 1, 2, 4-triazoles as proinflammatory cytokine inhibitors, Med. Chem. Res. 23 (2014), pp. 4250–4268. doi:10.1007/s00044-014-0989-x.
   Web of Science ®Google Scholar
• R. Shandil, M. Panda, C. Sadler, A. Ambady, V. Panduga, N. Kumar, J. Mahadevaswamy, M. Sreenivasaiah, A. Narayan, and S. Guptha, Scaffold morphing to identify novel dpre1 inhibitors with antimycobacterial activity, ACS. Med. Chem. Lett. 10 (2019), pp. 1480–1485. doi:10.1021/acsmedchemlett.9b00343.
   PubMed Web of Science ®Google Scholar
• S. Landge, A.B. Mullick, K. Nagalapur, J. Neres, V. Subbulakshmi, K. Murugan, A. Ghosh, C. Sadler, M.D. Fellows, and V. Humnabadkar, Discovery of benzothiazoles as antimycobac terial agents: Synthesis, structure–activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose 2′-oxidase, Bioorg. Med. Chem. 23 (2015), pp. 7694–7710. doi:10.1016/j.bmc.2015.11.017.
   PubMed Web of Science ®Google Scholar
• J. Gawad and C. Bonde, Design, synthesis and biological evaluation of some 2-(6-nitrobenzo [d] thiazol-2-ylthio)-N-benzyl-N-(6-nitrobenzo[d]thiazol-2-yl) acetamide derivatives as selective DprE1 inhibitors, Synth. Commun. 49 (2019), pp. 2696–2708. doi:10.1371/journal.pgen.0020088.
   Web of Science ®Google Scholar
• P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, B. Schwikowski, and T. Ideker, Cytoscape: A software environment for integrated models of biomolecular interaction networks, Genome Res. 13 (2003), pp. 2498–2504. doi:10.1101/gr.1239303.
   PubMed Web of Science ®Google Scholar
• M. Naik, V. Humnabadkar, S.J. Tantry, M. Panda, A. Narayan, A. Guptha, V. Panduga, P. Manjrekar, L.K. Jena, and K. Koushik, 4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity, J. Med. Chem. 57 (2014), pp. 5419–5434. doi:10.1021/jm5005978.
   PubMed Web of Science ®Google Scholar
• P.S. Shirude, R. Shandil, C. Sadler, M. Naik, V. Hosagrahara, S. Hameed, V. Shinde, C. Bathula, V. Humnabadkar, and N. Kumar, Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo, J. Med. Chem. 56 (2013), pp. 9701–9708. doi:10.1021/jm401382v.
   PubMed Web of Science ®Google Scholar
• P.S. Shirude, R.K. Shandil, M. Manjunatha, C. Sadler, M. Panda, V. Panduga, J. Reddy, R. Saralaya, R. Nanduri, and A. Ambady, Lead optimization of 1, 4-azaindoles as antimycobacterial agents, J. Med. Chem. 57 (2014), pp. 5728–5737. doi:10.1021/jm500571f.
   PubMed Web of Science ®Google Scholar
• M. Chatterji, R. Shandil, M. Manjunatha, S. Solapure, V. Ramachandran, N. Kumar, R. Saralaya, V. Panduga, J. Reddy, and K. Prabhakar, 1, 4-Azaindole, a potential drug candidate for treatment of tuberculosis, Antimicrob. Agents Chemother. 58 (2014), pp. 5325–5331. doi:10.1128/AAC.03233-14.
   PubMed Web of Science ®Google Scholar
• V.S. Pore, J.M. Divse, C.R. Charolkar, L.U. Nawale, V.M. Khedkar, and D. Sarkar, Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents, Bioorg. Med. Chem. Lett. 25 (2015), pp. 4185–4190. doi:10.1016/j.bmcl.2015.08.006.
   PubMed Web of Science ®Google Scholar
• V. Makarov, J. Neres, R.C. Hartkoorn, O.B. Ryabova, E. Kazakova, M. Šarkan, S. Huszár, J. Piton, G.S. Kolly, and A. Vocat, The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 59 (2015), pp. 4446–4452. doi:10.1128/AAC.00778-15.
   PubMedGoogle Scholar
• M.H. Shaikh, D.D. Subhedar, M. Arkile, V.M. Khedkar, N. Jadhav, D. Sarkar, and B.B. Shingate, Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent, Bioorg. Med. Chem. Lett. 26 (2016), pp. 561–569. doi:10.1016/j.bmcl.2015.11.071.
   PubMed Web of Science ®Google Scholar
• R. Chikhale, S. Menghani, R. Babu, R. Bansode, G. Bhargavi, N. Karodia, M. Rajasekharan, A. Paradkar, and P. Khedekar, Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides, Eur. J. Med. Chem. 96 (2015), pp. 30–46. doi:10.1016/j.ejmech.2015.04.011.
   PubMed Web of Science ®Google Scholar
• S.M. Batt, M. Cacho Izquierdo, J. Castro Pichel, C.J. Stubbs, L. Vela-Glez Del Peral, E. Pérez-Herrán, N. Dhar, B. Mouzon, M. Rees, and J.P. Hutchinson, Whole cell target engagement identifies novel inhibitors of Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose oxidase, ACS. Infect. Dis. 12 (2015), pp. 615–626. doi:10.1021/acsinfecdis.5b00065.
   Google Scholar
• T. Chitre, K. Asgaonkar, P. Miniyar, A. Dharme, M. Arkile, A. Yeware, D. Sarkar, V. Khedkar, and P. Jha, Synthesis and docking studies of pyrazine–thiazolidinone hybrid scaffold targeting dormant tuberculosis, Bioorg. Med. Chem. Lett. 26 (2016), pp. 2224–2228. doi:10.1016/j.bmcl.2016.03.055.
   PubMed Web of Science ®Google Scholar
• J. Neres, R.C. Hartkoorn, L.R. Chiarelli, R. Gadupudi, M.R. Pasca, G. Mori, A. Venturelli, S. Savina, V. Makarov, and G.S. Kolly, 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1, ACS Chem. Biol. 10 (2014), pp. 705–714. doi:10.1021/cb5007163.
   PubMed Web of Science ®Google Scholar
• M.H. Shaikh, D.D. Subhedar, L. Nawale, D. Sarkar, F.A.K. Khan, J.N. Sangshetti, and B.B. Shingate, 1, 2, 3-Triazole derivatives as antitubercular agents: Synthesis, biological evalu ation and molecular docking study, Med. Chem. Comm. 6 (2015), pp. 1104–1116. doi:10.1039/c5md00057b.
   Web of Science ®Google Scholar
• Ligprep, Version 2.5, User Manual, Schrödinger, LLC, New York, 2012.
   Google Scholar
• W.L. Jorgensen, D.S. Maxwell, and J. Tirado- Rives, Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids, J. Am. Chem. Soc. (1996), pp. 11225–11236. doi:10.1021/ja9621760.
   Web of Science ®Google Scholar
• PHASE, Version 3.4, Schrödinger, LLC, New York, 2012.
   Google Scholar
• B. Vyas, O. Silakari, M. Singh Bahia, and B. Singh, Glutamine: Fructose-6-phosphate amidotransferase (GFAT): Homology modelling and designing of new inhibitors using pharmacophore and docking based hierarchical virtual screening protocol, SAR QSAR Environ. Res. 24 (2013), pp. 733–752. doi:10.1080/1062.936X.2013.797493.
   PubMed Web of Science ®Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph. Model. 20 (2002), pp. 269–276. doi:10.1016/S1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• Glide, Version 5.8, User Manual, Schrödinger, LLC, New York, 2012.
   Google Scholar
• R. Schrödinger, Desmond Molecular Dynamics System, Vol. 4, DE Shaw Research, New York, 2015.
   Google Scholar
• P. Mark and L. Nilsson, Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K, J. Phys. Chem A 105 (2001), pp. 9954–9960. doi:10.1021/jp003020w.
   Web of Science ®Google Scholar
• S. Tinte, M.G. Stachiotti, S.R. Phillpot, M. Sepliarsky, D. Wolf, and R.L. Migoni, Ferroelectric properties of BaxSr1− xTiO3 solid solutions obtained by molecular dynamics simulation, J. Phys. Condens. Matter 16 (2004), pp. 3495–3506. doi:10.1088/0953-8984/16/20/019.
   Web of Science ®Google Scholar
• G.J. Martyna, D.J. Tobias, and M.L. Klein, Constant pressure molecular dynamics algorithms, J. Chem. Phys. 101 (1994), pp. 4177–4189. doi:10.1063/1.467468.
   Web of Science ®Google Scholar
• Prime, Version 3.1, Schrödinger, LLC, New York, NY, 2012.
   Google Scholar
• QikProp, Version 3.5, User Manual, Schrödinger, LLC, New York, NY, 2012.
   Google Scholar
• E.E. Smissman, J.B. Lapidus, and S.D. Beck, Isolation and synthesis of an insect resistance factor from corn plants, J. Am. Chem. Soc. 79 (1957), pp. 4697–4698. doi:10.1021/ja01574a032.
   Web of Science ®Google Scholar
• J. Neres, R.C. Hartkoorn, L.R. Chiarelli, R. Gadupudi, M.R. Pasca, G. Mori, A. Venturelli, S. Savina, V. Makarov, G.S. Kolly, and E. Molteni, 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1, ACS. Chem. Bio. 20 (2015), pp. 705–714. doi:10.1021/cb5007163.
   Google Scholar
• X. He and J. Zhang, Why do hubs tend to be essential in protein networks?, PLoS Genet. 2 (2006), pp. 826–834. doi:10.1371/journal.pgen.0020088.
   Web of Science ®Google Scholar